Cargando…

TREATMENT OF PERIOCULAR HYPERPIGMENTATION DUE TO LEAD OF KOHL (SURMA) BY PENICILLAMINE: A SINGLE GROUP NON-RANDOMIZED CLINICAL TRIAL

BACKGROUND: Periocular hyperpigmentation is a condition in which skin of eyelids become darker in color than the normal surrounding skin. Lead and other heavy metals produce increased pigmentation because of deposition of metal particles in the dermis and increased epidermal melanin production. AIMS...

Descripción completa

Detalles Bibliográficos
Autores principales: El Safoury, Omar Soliman, Abd El Fatah, Dina Sabry, Ibrahim, Magdy
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807714/
https://www.ncbi.nlm.nih.gov/pubmed/20101339
http://dx.doi.org/10.4103/0019-5154.57614
_version_ 1782176425117220864
author El Safoury, Omar Soliman
Abd El Fatah, Dina Sabry
Ibrahim, Magdy
author_facet El Safoury, Omar Soliman
Abd El Fatah, Dina Sabry
Ibrahim, Magdy
author_sort El Safoury, Omar Soliman
collection PubMed
description BACKGROUND: Periocular hyperpigmentation is a condition in which skin of eyelids become darker in color than the normal surrounding skin. Lead and other heavy metals produce increased pigmentation because of deposition of metal particles in the dermis and increased epidermal melanin production. AIMS: This study was conducted to evaluate the dual effect of chelation therapy in treating periocular hyperpigmentation and lead toxicity. METHODS: The study population consisted of nine females complaining from dark coloration of their eyelids. The nine females were continuously using kohl as eyeliner. Lead levels in conjunctiva and serum before and after D-penicillamine (D-PCN) oral administration were estimated in relation to vertical, horizontal length, and degree of hyperpigmentation score. RESULTS: Highly significant P values (0.000) were obtained as regard to the conjunctival lead levels, serum lead levels, horizontal length, and degree of darkness score before and after D-PCN therapy. A less significant P value (0.040) was recorded as regard to the vertical length. CONCLUSION: Regardless other causes, this study spots the light on a new concept for periocular hyperpigmentation from lead toxicity in adult females using kohl and suggests D-PCN in a low divided dose (750 mg/day) for its treatment.
format Text
id pubmed-2807714
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-28077142010-01-25 TREATMENT OF PERIOCULAR HYPERPIGMENTATION DUE TO LEAD OF KOHL (SURMA) BY PENICILLAMINE: A SINGLE GROUP NON-RANDOMIZED CLINICAL TRIAL El Safoury, Omar Soliman Abd El Fatah, Dina Sabry Ibrahim, Magdy Indian J Dermatol Therapeutic Round BACKGROUND: Periocular hyperpigmentation is a condition in which skin of eyelids become darker in color than the normal surrounding skin. Lead and other heavy metals produce increased pigmentation because of deposition of metal particles in the dermis and increased epidermal melanin production. AIMS: This study was conducted to evaluate the dual effect of chelation therapy in treating periocular hyperpigmentation and lead toxicity. METHODS: The study population consisted of nine females complaining from dark coloration of their eyelids. The nine females were continuously using kohl as eyeliner. Lead levels in conjunctiva and serum before and after D-penicillamine (D-PCN) oral administration were estimated in relation to vertical, horizontal length, and degree of hyperpigmentation score. RESULTS: Highly significant P values (0.000) were obtained as regard to the conjunctival lead levels, serum lead levels, horizontal length, and degree of darkness score before and after D-PCN therapy. A less significant P value (0.040) was recorded as regard to the vertical length. CONCLUSION: Regardless other causes, this study spots the light on a new concept for periocular hyperpigmentation from lead toxicity in adult females using kohl and suggests D-PCN in a low divided dose (750 mg/day) for its treatment. Medknow Publications 2009 /pmc/articles/PMC2807714/ /pubmed/20101339 http://dx.doi.org/10.4103/0019-5154.57614 Text en © Indian Journal of Dermatology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Therapeutic Round
El Safoury, Omar Soliman
Abd El Fatah, Dina Sabry
Ibrahim, Magdy
TREATMENT OF PERIOCULAR HYPERPIGMENTATION DUE TO LEAD OF KOHL (SURMA) BY PENICILLAMINE: A SINGLE GROUP NON-RANDOMIZED CLINICAL TRIAL
title TREATMENT OF PERIOCULAR HYPERPIGMENTATION DUE TO LEAD OF KOHL (SURMA) BY PENICILLAMINE: A SINGLE GROUP NON-RANDOMIZED CLINICAL TRIAL
title_full TREATMENT OF PERIOCULAR HYPERPIGMENTATION DUE TO LEAD OF KOHL (SURMA) BY PENICILLAMINE: A SINGLE GROUP NON-RANDOMIZED CLINICAL TRIAL
title_fullStr TREATMENT OF PERIOCULAR HYPERPIGMENTATION DUE TO LEAD OF KOHL (SURMA) BY PENICILLAMINE: A SINGLE GROUP NON-RANDOMIZED CLINICAL TRIAL
title_full_unstemmed TREATMENT OF PERIOCULAR HYPERPIGMENTATION DUE TO LEAD OF KOHL (SURMA) BY PENICILLAMINE: A SINGLE GROUP NON-RANDOMIZED CLINICAL TRIAL
title_short TREATMENT OF PERIOCULAR HYPERPIGMENTATION DUE TO LEAD OF KOHL (SURMA) BY PENICILLAMINE: A SINGLE GROUP NON-RANDOMIZED CLINICAL TRIAL
title_sort treatment of periocular hyperpigmentation due to lead of kohl (surma) by penicillamine: a single group non-randomized clinical trial
topic Therapeutic Round
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807714/
https://www.ncbi.nlm.nih.gov/pubmed/20101339
http://dx.doi.org/10.4103/0019-5154.57614
work_keys_str_mv AT elsafouryomarsoliman treatmentofperiocularhyperpigmentationduetoleadofkohlsurmabypenicillamineasinglegroupnonrandomizedclinicaltrial
AT abdelfatahdinasabry treatmentofperiocularhyperpigmentationduetoleadofkohlsurmabypenicillamineasinglegroupnonrandomizedclinicaltrial
AT ibrahimmagdy treatmentofperiocularhyperpigmentationduetoleadofkohlsurmabypenicillamineasinglegroupnonrandomizedclinicaltrial